Transition from gynaecomastia to lipomastia in pubertal boys.
IGF-1
IGFBP-3
androgens
dihydrotestosterone
gynaecomastia
oestradiol
oestrogens
pseudogynaecomastia
testosterone
Journal
Clinical endocrinology
ISSN: 1365-2265
Titre abrégé: Clin Endocrinol (Oxf)
Pays: England
ID NLM: 0346653
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
14
12
2020
received:
30
09
2020
accepted:
16
12
2020
pubmed:
23
12
2020
medline:
13
8
2021
entrez:
22
12
2020
Statut:
ppublish
Résumé
Gynaecomastia is frequent in pubertal boys and is regarded as a self-limiting abnormality. However, longitudinal studies proving this hypothesis are scarce. Longitudinal follow-up study (median 2.4, range 1.0-4.8 years). The regression of breast diameter was analysed in 31 pubertal boys aged 11.7-16.1 (median 13.2) years with gynaecomastia. Furthermore, weight changes (as BMI-SDS) and pubertal stage, oestradiol [E2], oestriol, oestrone, androstenedione, testosterone [T], dihydrotestosterone, gonadotropins, IGF-1, and IGFBP-3 serum concentrations determined at first clinical presentation were related to breast diameter regression determined by palpation and disappearance of breast glandular tissue in ultrasound in follow-up to identify possible predictors of breast regression. During the observation period, the breast diameter decreased (in median -1 (interquartile range [IQR] -5 to +1) cm). At follow-up, 6% of boys had no breast enlargement any more, and 65% developed lipomastia. Gynaecomastia was still present in 29%. None of the analysed hormones was related significantly to breast diameter regression or disappearance of breast glandular tissue. In multiple linear regression analyses adjusted for observational period, as well as age and BMI-SDS at first presentation, changes in BMI-SDS (β-coefficient 6.0 ± 2.3, p = .015) but not the E2/T ratio or any other hormone determined at baseline was related to changes in breast diameter. Breast diameter regression seems not to be predictable by a hormone profile in pubertal boys with gynaecomastia. In pubertal boys presenting with gynaecomastia, conversion to lipomastia of smaller volume is common. The reduction of weight status was the best predictor of breast diameter regression.
Substances chimiques
Androgens
0
Testosterone
3XMK78S47O
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
583-589Informations de copyright
© 2020 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.
Références
Soliman AT, De Sanctis V, Yassin M. Management of adolescent gynaecomastia: an update. Acta Biomed. 2017;88:204-213.
Jones KN. Imaging of the adolescent breast. Semin Plast Surg. 2013;27:29-35.
Reinehr T, Kulle A, Barth A, Ackermann J, Lass N, Holterhus PM. Sex hormone profile in pubertal boys with gynaecomastia and pseudogynaecomastia. J Clin Endocrinol Metab. 2020;105:dgaa044.
Sansone A, Romanelli F, Sansone M, Lenzi A, Di LL. Gynaecomastia and hormones. Endocrine. 2017;55:37-44.
Braunstein GD. Gynaecomastia. N Engl J Med. 1993;328:490-495.
Al Alwan I, Al Azkawi H, Badri M, Tamim H, Al Dubayee M, Tamimi W. Hormonal, anthropometric and lipid factors associated with idiopathic pubertal gynaecomastia. Ann Saudi Med. 2013;33:579-583.
Mieritz MG, Raket LL, Hagen CP, et al. A longitudinal study of growth, sex steroids, and IGF-1 in Boys with physiological gynaecomastia. J Clin Endocrinol Metab. 2015;100:3752-3759.
Biro FM, Lucky AW, Huster GA, Morrison JA. Hormonal studies and physical maturation in adolescent gynaecomastia. J Pediatr. 1990;116:450-455.
Mieritz MG, Sorensen K, Aksglaede L, et al. Elevated serum IGF-I, but unaltered sex steroid levels, in healthy boys with pubertal gynaecomastia. Clin Endocrinol (Oxf). 2014;80:691-698.
Lee PA. The relationship of concentrations of serum hormones to pubertal gynaecomastia. J Pediatr. 1975;86:212-215.
Kumanov P, Deepinder F, Robeva R, Tomova A, Li J, Agarwal A. Relationship of adolescent gynaecomastia with varicocele and somatometric parameters: a cross-sectional study in 6200 healthy boys. J Adolesc Health. 2007;41:126-131.
Kulle AE, Riepe FG, Melchior D, Hiort O, Holterhus PM. A novel ultrapressure liquid chromatography tandem mass spectrometry method for the simultaneous determination of androstenedione, testosterone, and dihydrotestosterone in pediatric blood samples: age- and sex-specific reference data. J Clin Endocrinol Metab. 2010;95:2399-2409.
Cole TJ. The LMS method for constructing normalized growth standards. Eur J Clin Nutr. 1990;44:45-60.
Kromeyer-Hauschild K, Wabitsch M, Geller F, et al. Percentiles of body mass index in children and adolescents evaluated from different regional German studies. Monatsschr Kinderheilkd. 2001;149:807-818.
Sarica O, Kahraman AN, Ozturk E, Teke M. Efficiency of imaging modalities in male breast disease: can ultrasound give additional information for assessment of gynaecomastia evolution? Eur J Breast Health. 2018;14:29-34.
Garcia CJ, Espinoza A, Dinamarca V, et al. Breast US in children and adolescents. Radiographics. 2000;20:1605-1612.
Altmeyer P, el-Gammel S, Hoffmann K. Ultrasound in Dermatology, 1st edn. Heidelberg New York: Springer Verlag Berlin; 1992.
Ng ST, Zhou J, Adesanya OO, Wang J, LeRoith D, Bondy CA. Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nat Med. 1997;3:1141-1144.
Acharya SV, Gopal RA, Bandgar TR, Menon PS, Shah NS. Prepubertal gynaecomastia a rare complication of growth hormone therapy. Indian J Pediatr. 2010;77:443-444.
Lorek M, Tobolska-Lorek D, Kalina-Faska B, Trzciakowska A, Gawlik A. Clinical and biochemical phenotype of adolescent males with gynaecomastia. J Clin Res Pediatr Endocrinol. 2019;11:388-394.
Aluclu MA, Sen S, Cevik M. Association between plasma kisspeptin levels and adolescent gynaecomastia. Afr J Paediatr Surg. 2016;13:136-139.
Rivera NF, Eisenstein E, Cardoso CB. The relation between pubertal gynaecomastia and body mass index in a sample of adolescents attended at the Outpatient Health Unit of a University Hospital. Arq Bras Endocrinol Metabol. 2009;53:435-439.
Rege J, Turcu AF, Kasa-Vubu JZ, et al. 11-Ketotestosterone Is the dominant circulating bioactive androgen during normal and premature adrenarche. J Clin Endocrinol Metab. 2018;103:4589-4598.
Turcu AF, Nanba AT, Auchus RJ. The rise, fall, and resurrection of 11-oxygenated androgens in human physiology and disease. Horm Res Paediatr. 2018;89:284-291.
Masamura S, Santner SJ, Santen RJ. Evidence of in situ estrogen synthesis in nitrosomethylurea-induced rat mammary tumors via the enzyme estrone sulfatase. J Steroid Biochem Mol Biol. 1996;58:425-429.
Slominski A, Zbytek B, Nikolakis G, et al. Steroidogenesis in the skin: implications for local immune functions. J Steroid Biochem Mol Biol. 2013;137:107-123.